查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1579395

自體幹細胞/非幹細胞治療市場：按類型、適應症和最終用戶分類 - 2025-2030 年全球預測

Autologous Stem Cell & Non-Stem Cell Therapies Market by Type (Autologous Non-Stem Cells, Autologous Stem Cells), Indication (Cancer, Cardiovascular Disease, Neurodegenerative Disorders), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

自體幹細胞/非幹細胞治療市場2023年估值為46.7億美元，預計2024年將達到52.8億美元，複合年成長率為14.45%，至2030年將達到120.1億美元。

在自體和非自體幹細胞治療領域，患者自身的細胞被用來治療和預防疾病。這些治療方法具有廣泛的應用，從再生醫學到癌症和自體免疫疾病的治療。需要這些治療方法是因為可以減少排斥反應、降低併發症風險以及個人化治療方法，與傳統方法相比具有顯著優勢。主要最終用途領域包括醫療機構、研究機構和生技公司。市場成長受到細胞處理技術進步、研究經費增加以及人口老化導致的未滿足醫療需求增加的顯著影響。此外，核准創新治療方法的監管支持進一步支持了這些治療方法的採用。開拓先進的細胞處理技術和進入醫療保健系統不足的新興市場存在商機。可客製化治療方法和技術共用的合作研究也提供了良好的前景。然而，市場面臨治療成本高、監管障礙以及細胞收集和應用方面的倫理問題等挑戰。此外，治療的擴充性和一致的品管增加了複雜性。創新的最佳途徑包括研究提高細胞活力和壽命、增強傳遞機制以及最佳化儲存解決方案。此外，利用機器學習在治療方法開發和患者結果評估中進行預測建模可以提供競爭優勢。整體而言，自體和非自體幹細胞治療市場是一個充滿活力的市場，其特點是快速的技術創新和有希望的成長機會，但必須仔細掌握監管環境和倫理考量。與監管機構和相關人員的積極合作有助於克服障礙並促進更順利的市場進入和擴張。

主要市場統計
基準年[2023] 46.7億美元
預測年份 [2024] 52.8億美元
預測年份 [2030] 120.1億美元
複合年成長率（%） 14.45%

市場動態：快速發展的自體幹細胞和非幹細胞治療市場的關鍵市場洞察

自體幹細胞和非幹細胞治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 慢性病盛行率增加
    • 再生醫學技術的進展
    • 對個人化醫療的認知和接受度不斷提高
  • 市場限制因素
    • 由於臨床資料有限，家庭療法的長期有效性尚不確定
  • 市場機會
    • 擴大基因編輯技術研究
    • 政府扶持政策與經費推動自體幹細胞應用研發
  • 市場挑戰
    • 自體幹細胞治療的嚴格法規和核准流程

波特的五力：駕馭自體幹細胞/非幹細胞治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對自體幹細胞/非幹細胞治療市場的影響

外部宏觀環境因素在塑造自體幹細胞和非幹細胞治療市場的動態表現方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解自體幹細胞/非幹細胞治療市場的競爭狀況

自體幹細胞和非幹細胞治療市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣自體幹細胞/非幹細胞治療市場供應商績效評估

FPNV定位矩陣是評估自體幹細胞和非幹細胞治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，描繪自體幹細胞和非幹細胞治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，自體幹細胞和非幹細胞治療市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病增加
      • 再生醫學技術的進展
      • 對個人化醫療的認知和接受度不斷提高
    • 抑制因素
      • 有限的臨床資料對自體免疫療法的長期療效產生了不確定性
    • 機會
      • 擴大基因編輯技術研究
      • 政府扶持政策和經費將促進自體幹細胞應用研發
    • 任務
      • 自體幹細胞治療的嚴格監管障礙和核准流程
  • 市場區隔分析
    • 類型：探討自體幹細胞的進展及其對血液學、心血管和腫瘤學治療的影響
    • 最終使用者：研究設施對自體幹細胞和非幹細胞治療的影響
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章自體幹細胞/非幹細胞治療市場：依類型

  • 自體非幹細胞
    • CAR-T細胞療法
    • 腫瘤浸潤淋巴細胞
  • 自體幹細胞

第7章自體幹細胞/非幹細胞治療市場（依適應症）

  • 癌症
  • 心血管疾病
  • 神經退化性疾病
  • 整形外科疾病

第8章自體幹細胞/非幹細胞治療市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 研究設施

第9章 美洲自體幹細胞/非幹細胞治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章 亞太地區自體幹細胞/非幹細胞治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲自體幹細胞/非幹細胞治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 百時美施貴寶的 Breyanzi 獲得 FDA 優先核准，這是一種治療某些血液癌症的新型 CAR T 細胞療法
    • FDA核准針對多發性骨髓瘤患者的新幹細胞動員療法
  • 戰略分析和建議

公司名單

  • Anterogen Co., Ltd.
  • Bluebird Bio, Inc.
  • Brainstorm Cell Therapeutics, Inc.
  • Caladrius Biosciences, Inc.
  • Castle Creek Biosciences Inc.
  • Cytori Therapeutics Inc.
  • Dendreon Pharmaceuticals LLC
  • Gilead Sciences, Inc.
  • HCA International Limited
  • Hemogenyx Pharmaceuticals PLC
  • Hemostemix Inc.
  • Jasper Therapeutics, Inc.
  • Juventas Therapeutics, Inc.
  • Kolon TissueGene, Inc.
  • Medipost Co., Ltd.
  • NOVADIP Biosciences SA
  • Novartis AG
  • NuVasive, Inc.
  • Opexa Therapeutics, Inc.
  • Regeneus Ltd. by Cambium-Cambium Bio Limited
  • Reliance Life Sciences Pvt. Ltd.
  • Stempeutics Research Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vericel Corporation
Product Code: MRR-030C42D3EDB5

The Autologous Stem Cell & Non-Stem Cell Therapies Market was valued at USD 4.67 billion in 2023, expected to reach USD 5.28 billion in 2024, and is projected to grow at a CAGR of 14.45%, to USD 12.01 billion by 2030.

The field of autologous stem cell and non-stem cell therapies involves using a patient's own cells to treat or prevent diseases. These therapies have broad applications, ranging from regenerative medicine to cancer and autoimmune disorder treatment. The necessity of these therapies stems from their potential for reduced rejection rates, lower risk of complications, and personalized treatment approaches, offering significant advantages over traditional methodologies. Key end-use sectors include healthcare institutions, research organizations, and biotech firms. Market growth is heavily influenced by technological advancements in cell processing, increasing funding for research, and the growing unmet medical needs of aging populations. Moreover, regulatory support in approving innovative therapies is further driving the adoption of these treatment modalities. Opportunities beckon in the development of advanced cell processing techniques and expanding into untapped markets with healthcare system inadequacies. Customizable therapeutic approaches and collaborations for technology sharing also present lucrative prospects. However, the market faces challenges such as high treatment costs, regulatory hurdles, and ethical concerns regarding cell harvesting and application. Moreover, scalability and consistent quality control of therapies add to the complexity. The best paths for innovation include research into improving cell viability and longevity, enhancing delivery mechanisms, and optimizing storage solutions. Additionally, leveraging machine learning for predictive modeling in therapy development and patient outcome assessments can offer competitive advantages. Overall, the market for autologous stem cell and non-stem cell therapies is dynamic, characterized by rapid technological innovations and promising growth opportunities, but requires careful navigation through regulatory landscapes and ethical considerations. Engaging in proactive collaboration with regulatory bodies and stakeholders can help surmount barriers and facilitate smoother market entry and expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 4.67 billion
Estimated Year [2024] USD 5.28 billion
Forecast Year [2030] USD 12.01 billion
CAGR (%) 14.45%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Autologous Stem Cell & Non-Stem Cell Therapies Market

The Autologous Stem Cell & Non-Stem Cell Therapies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of chronic diseases
    • Advancements in regenerative medicine technology
    • Rising awareness and acceptance of personalized medicine
  • Market Restraints
    • Limited clinical data creating uncertainty regarding the long-term efficacy of autologous therapies
  • Market Opportunities
    • Expanding research in gene editing technology
    • Supportive government policies and funding boost R&D in autologous stem cell applications
  • Market Challenges
    • Stringent Regulatory hurdles & approval process for autologous stem cell therapies

Porter's Five Forces: A Strategic Tool for Navigating the Autologous Stem Cell & Non-Stem Cell Therapies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Autologous Stem Cell & Non-Stem Cell Therapies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Autologous Stem Cell & Non-Stem Cell Therapies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Autologous Stem Cell & Non-Stem Cell Therapies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Autologous Stem Cell & Non-Stem Cell Therapies Market

A detailed market share analysis in the Autologous Stem Cell & Non-Stem Cell Therapies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Autologous Stem Cell & Non-Stem Cell Therapies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Autologous Stem Cell & Non-Stem Cell Therapies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Autologous Stem Cell & Non-Stem Cell Therapies Market

A strategic analysis of the Autologous Stem Cell & Non-Stem Cell Therapies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Autologous Stem Cell & Non-Stem Cell Therapies Market, highlighting leading vendors and their innovative profiles. These include Anterogen Co., Ltd., Bluebird Bio, Inc., Brainstorm Cell Therapeutics, Inc., Caladrius Biosciences, Inc., Castle Creek Biosciences Inc., Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC, Gilead Sciences, Inc., HCA International Limited, Hemogenyx Pharmaceuticals PLC, Hemostemix Inc., Jasper Therapeutics, Inc., Juventas Therapeutics, Inc., Kolon TissueGene, Inc., Medipost Co., Ltd., NOVADIP Biosciences S.A., Novartis AG, NuVasive, Inc., Opexa Therapeutics, Inc., Regeneus Ltd. by Cambium - Cambium Bio Limited, Reliance Life Sciences Pvt. Ltd., Stempeutics Research Pvt. Ltd., Takeda Pharmaceutical Company Limited, and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Autologous Stem Cell & Non-Stem Cell Therapies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Autologous Non-Stem Cells and Autologous Stem Cells. The Autologous Non-Stem Cells is further studied across Car T Cell Therapies and Tumor Infiltrating Lymphocyte.
  • Based on Indication, market is studied across Cancer, Cardiovascular Disease, Neurodegenerative Disorders, and Orthopedic Diseases.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Research Facilities.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic diseases
      • 5.1.1.2. Advancements in regenerative medicine technology
      • 5.1.1.3. Rising awareness and acceptance of personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Limited clinical data creating uncertainty regarding the long-term efficacy of autologous therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding research in gene editing technology
      • 5.1.3.2. Supportive government policies and funding boost R&D in autologous stem cell applications
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent Regulatory hurdles & approval process for autologous stem cell therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Exploring Advancements in Autologous Stem Cell, Impacts on Hematological, Cardiovascular, and Oncology Treatments
    • 5.2.2. End-User: Impact of Research Facilities in Autologous Stem Cell & Non-Stem Cell Therapies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type

  • 6.1. Introduction
  • 6.2. Autologous Non-Stem Cells
    • 6.2.1. Car T Cell Therapies
    • 6.2.2. Tumor Infiltrating Lymphocyte
  • 6.3. Autologous Stem Cells

7. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication

  • 7.1. Introduction
  • 7.2. Cancer
  • 7.3. Cardiovascular Disease
  • 7.4. Neurodegenerative Disorders
  • 7.5. Orthopedic Diseases

8. Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Research Facilities

9. Americas Autologous Stem Cell & Non-Stem Cell Therapies Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Autologous Stem Cell & Non-Stem Cell Therapies Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Autologous Stem Cell & Non-Stem Cell Therapies Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Bristol Myers Squibb Gets FDA Fast-Track for New CAR T Cell Therapy Breyanzi to Treat Certain Blood Cancers
    • 12.3.2. FDA Approves New Stem Cell Mobilization Therapy for Multiple Myeloma Patients
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Anterogen Co., Ltd.
  • 2. Bluebird Bio, Inc.
  • 3. Brainstorm Cell Therapeutics, Inc.
  • 4. Caladrius Biosciences, Inc.
  • 5. Castle Creek Biosciences Inc.
  • 6. Cytori Therapeutics Inc.
  • 7. Dendreon Pharmaceuticals LLC
  • 8. Gilead Sciences, Inc.
  • 9. HCA International Limited
  • 10. Hemogenyx Pharmaceuticals PLC
  • 11. Hemostemix Inc.
  • 12. Jasper Therapeutics, Inc.
  • 13. Juventas Therapeutics, Inc.
  • 14. Kolon TissueGene, Inc.
  • 15. Medipost Co., Ltd.
  • 16. NOVADIP Biosciences S.A.
  • 17. Novartis AG
  • 18. NuVasive, Inc.
  • 19. Opexa Therapeutics, Inc.
  • 20. Regeneus Ltd. by Cambium - Cambium Bio Limited
  • 21. Reliance Life Sciences Pvt. Ltd.
  • 22. Stempeutics Research Pvt. Ltd.
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET RESEARCH PROCESS
  • FIGURE 2. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET DYNAMICS
  • TABLE 7. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CAR T CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TUMOR INFILTRATING LYMPHOCYTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY ORTHOPEDIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY RESEARCH FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023